Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors - Summary - MDSpire

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • By

  • Ting-Kai Liao

  • Wei-Hsun Lu

  • Ping-Jui Su

  • Chih-Jung Wang

  • Ying Jui Chao

  • Yan-Shen Shan

  • May 28, 2026

  • 0 min

Share

Objective:

Emphasize the significance of identifying predictive factors for optimal NAC benefit.

Key Findings:
  • Add specific data or statistics to support claims about NAC improving outcomes.
Interpretation:

Elaborate on the implications of findings for clinical practice.

Limitations:
  • Add more limitations related to potential confounding factors.
Conclusion:

Reiterate the importance of findings in the context of current treatment debates.

Original Source(s)

Survival benefits of neoadjuvant chemotherapy in advanced pancreatic cancer with vascular resection: who benefits the most? A study on key predictive factors

  • by Ting-Kai Liao, Wei-Hsun Lu, Ping-Jui Su, Chih-Jung Wang, Ying Jui Chao, Yan-Shen Shan

  • May 28, 2026

Related Content

Advancing glioblastoma research by establishing a whole brain slice model

Evolution of the prostate cancer diagnostic paradigm: integrated evidence and clinical pathways from targeted biopsy to biopsy-free strategy

Case Report: First report of PIK3CA-related overgrowth spectrum revealed by refractory chylorrhea after breast-conserving surgery: failed thoracic-duct ligation